Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419419 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
A Phase 3 study of Autoimmune Diseases and Scleroderma, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT00419419 is a Phase 3 study of Autoimmune Diseases and Scleroderma that has completed, run by MediQuest Therapeutics. The registered enrollment target is 80 participants, below the 975-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT00419419, a Phase 3 study of Autoimmune Diseases and Scleroderma, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
Conditions Studied
Interventions
- DRUG Topical AmphiMatrix with nitroglycerin (MQX-503)
Study Locations (12)
Other
- Lund University Hospital - Lund
- Royal National Hospital for Rheumatic Diseases - Bath
- Ninewells Hospital and Medical School - Dundee
- University of Leeds - Leeds
- Royal Free Hospital - London
- Hope Hospital - Salford
California
- Standford Medical School - Stanford
Connecticut
- University of Connecticut - Farmington
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
New York
- The Center for Rheumatology - Albany
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419419
The ClinicalTrials.gov registry entry for NCT00419419 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 975-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (92% lower). The listed sponsor is MediQuest Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 1 intervention - of which Topical AmphiMatrix with nitroglycerin (MQX-503) is the first listed.
NCT00419419 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00419419 about?
NCT00419419 is a clinical study titled "Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon". The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
What is the current status of trial NCT00419419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2006-12.
What conditions does trial NCT00419419 study?
This clinical trial studies the following conditions: Autoimmune Diseases, Scleroderma, Raynaud's Disease.
What interventions are being tested in trial NCT00419419?
The interventions under investigation include: Topical AmphiMatrix with nitroglycerin (MQX-503) (DRUG).
Who is sponsoring clinical trial NCT00419419?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419419 being conducted?
This trial has 12 study locations across California, Connecticut, District of Columbia, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ovarian Tissue Cryopreservation for Fertility Preservation
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.